{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:08:16Z","timestamp":1790006896646,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"DOI":"10.1007\/s40272-026-00778-x","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:54:13Z","timestamp":1790006053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Ocrelizumab and Ofatumumab Treatment in Pediatric-Onset Multiple Sclerosis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-4268","authenticated-orcid":false,"given":"Vivien X.","family":"Xie Cherng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Har","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Kornbluh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1212\/01.wnl.0000259422.44235.a8","volume":"68","author":"LB Krupp","year":"2007","unstructured":"Krupp LB, Banwell B, Tenembaum S, International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68:S7-12. https:\/\/doi.org\/10.1212\/01.wnl.0000259422.44235.a8.","journal-title":"Neurology"},{"key":"778_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3062","author":"LH Hua","year":"2024","unstructured":"Hua LH, Solomon AJ, Tenembaum S, Scalfari A, Rovira \u00c0, Rostasy K, et al. Differential diagnosis of suspected multiple sclerosis in pediatric and late-onset populations: a review. JAMA Neurol. 2024. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3062.","journal-title":"JAMA Neurol"},{"key":"778_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","volume":"20","author":"G Fadda","year":"2021","unstructured":"Fadda G, Armangue T, Hacohen Y, Chitnis T, Banwell B. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol. 2021;20:136\u201349. https:\/\/doi.org\/10.1016\/S1474-4422(20)30432-4.","journal-title":"Lancet Neurol"},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/jnnp-2025-336680","volume":"97","author":"D Ellenberger","year":"2026","unstructured":"Ellenberger D, Flachenecker P, Haas J, Hellwig K, P\u00f6hlau D, Stahmann A, et al. Paediatric-onset multiple sclerosis: demographics, symptoms and disease progression. J Neurol Neurosurg Psychiatry. 2026;97:175\u201382. https:\/\/doi.org\/10.1136\/jnnp-2025-336680.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1191\/1352458502ms786oa","volume":"8","author":"A Ghezzi","year":"2002","unstructured":"Ghezzi A, Pozzilli C, Liguori M, Marrosu MG, Milani N, Milanese C, et al. Prospective study of multiple sclerosis with early onset. Mult Scler. 2002;8:115\u20138. https:\/\/doi.org\/10.1191\/1352458502ms786oa.","journal-title":"Mult Scler"},{"key":"778_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1352458511430704","volume":"18","author":"T Chitnis","year":"2012","unstructured":"Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18:116\u201327. https:\/\/doi.org\/10.1177\/1352458511430704.","journal-title":"Mult Scler"},{"key":"778_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2023.101054","volume":"46","author":"AB Kornbluh","year":"2023","unstructured":"Kornbluh AB, Kahn I. Pediatric multiple sclerosis. Semin Pediatr Neurol. 2023;46:101054. https:\/\/doi.org\/10.1016\/j.spen.2023.101054.","journal-title":"Semin Pediatr Neurol"},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/jamaneurol.2023.5566","volume":"81","author":"N Benallegue","year":"2024","unstructured":"Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, et al. Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis. JAMA Neurol. 2024;81:273\u201382. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5566.","journal-title":"JAMA Neurol"},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2025.04.003","volume":"168","author":"P Panahi","year":"2025","unstructured":"Panahi P, Mirzohreh ST, Zafardoust H, Habibi P, Ghojazadeh M, Shoaran M. Pediatric multiple sclerosis: a systematic exploration of effectiveness in current and emerging therapeutics. Pediatr Neurol. 2025;168:23\u201359. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2025.04.003.","journal-title":"Pediatr Neurol"},{"key":"778_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2352-4642(24)00047-6","volume":"8","author":"S Sharmin","year":"2024","unstructured":"Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, et al. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Lancet Child Adolesc Health. 2024;8:348\u201357. https:\/\/doi.org\/10.1016\/S2352-4642(24)00047-6.","journal-title":"Lancet Child Adolesc Health"},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40893-018-0037-7","volume":"3","author":"S Ruggieri","year":"2018","unstructured":"Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Mult Scler Demyelinating Disord. 2018;3:5. https:\/\/doi.org\/10.1186\/s40893-018-0037-7.","journal-title":"Mult Scler Demyelinating Disord."},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1352458517732843","volume":"25","author":"P Huppke","year":"2019","unstructured":"Huppke P, Huppke B, Ellenberger D, Rostasy K, Hummel H, Stark W, et al. Therapy of highly active pediatric multiple sclerosis. Mult Scler. 2019;25:72\u201380. https:\/\/doi.org\/10.1177\/1352458517732843.","journal-title":"Mult Scler"},{"key":"778_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25737","volume":"88","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol. 2020;88:42\u201355. https:\/\/doi.org\/10.1002\/ana.25737.","journal-title":"Ann Neurol"},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ana.26052","volume":"89","author":"E De Meo","year":"2021","unstructured":"De Meo E, Bonacchi R, Moiola L, Colombo B, Sangalli F, Zanetta C, et al. Early predictors of 9-year disability in pediatric multiple sclerosis. Ann Neurol. 2021;89:1011\u201322. https:\/\/doi.org\/10.1002\/ana.26052.","journal-title":"Ann Neurol"},{"key":"778_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001008","volume":"8","author":"OA Abdel-Mannan","year":"2021","unstructured":"Abdel-Mannan OA, Manchoon C, Rossor T, Southin J-C, Tur C, Brownlee W, et al. Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1008. https:\/\/doi.org\/10.1212\/NXI.0000000000001008.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"778_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208114","volume":"102","author":"T Spelman","year":"2024","unstructured":"Spelman T, Simoneau G, Hyde R, Kuhelj R, Alroughani R, Ozakbas S, et al. Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: a registry-based study. Neurology. 2024;102:e208114. https:\/\/doi.org\/10.1212\/WNL.0000000000208114.","journal-title":"Neurology"},{"key":"778_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","volume":"379","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Arnold DL, Banwell B, Br\u00fcck W, Ghezzi A, Giovannoni G, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379:1017\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1800149.","journal-title":"N Engl J Med"},{"key":"778_CR18","unstructured":"Genentech. FDA approves Ocrevus for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older. 2026. https:\/\/www.gene.com\/media\/statements\/ps_050826. Accessed 11 Sept 2026."},{"key":"778_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"key":"778_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"778_CR21","unstructured":"A study to evaluate safety and efficacy of ocrelizumab in comparison with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis (RRMS) (Operetta 2). https:\/\/clinicaltrials.gov\/study\/NCT05123703. Accessed 23 Mar 2026."},{"key":"778_CR22","unstructured":"Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis (NEOS). https:\/\/clinicaltrials.gov\/study\/NCT04926818. Accessed 23 Mar 2026."},{"key":"778_CR23","unstructured":"A study of ocrelizumab in children and adolescents with relapsing-remitting multiple sclerosis. https:\/\/clinicaltrials.gov\/study\/NCT04075266. Accessed 23 Mar 2026."},{"key":"778_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2017","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017;17:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"778_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24:850\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4.","journal-title":"Lancet Neurol"},{"key":"778_CR26","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149:1525\u201360. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025.","journal-title":"J Allergy Clin Immunol"},{"key":"778_CR27","unstructured":"Cancer Therapy Evaluation Program Division of Cancer Therapy and Diagnosis National Cancer Institute National Institutes of Health U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0). 2025."},{"key":"778_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22:268\u201382. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8.","journal-title":"Lancet Neurol"},{"key":"778_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.18553\/jmcp.2021.27.9.1273","volume":"27","author":"J Mardan","year":"2021","unstructured":"Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021;27:1273\u201395. https:\/\/doi.org\/10.18553\/jmcp.2021.27.9.1273.","journal-title":"J Manag Care Spec Pharm"},{"key":"778_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.14412\/2074-2711-2025-1-72-77","volume":"17","author":"ED Kuzminykh","year":"2025","unstructured":"Kuzminykh ED, Lebedev VM, Senchenko VE, Cherepyansky MS, Gonchar VA, Korobko DS. The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia: a case series. Neurol Neuropsychiatr Psychosom. 2025;17:72\u20137. https:\/\/doi.org\/10.14412\/2074-2711-2025-1-72-77.","journal-title":"Neurol Neuropsychiatr Psychosom"},{"key":"778_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/13524585231223069","volume":"30","author":"M Venet","year":"2024","unstructured":"Venet M, Lepine A, Maarouf A, Biotti D, Boutiere C, Casez O, et al. Control of disease activity with large extended-interval dosing of rituximab\/ocrelizumab in highly active pediatric multiple sclerosis. Mult Scler. 2024;30:261\u20135. https:\/\/doi.org\/10.1177\/13524585231223069.","journal-title":"Mult Scler"},{"key":"778_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2023.04.020","volume":"145","author":"N Malani Shukla","year":"2023","unstructured":"Malani Shukla N, Casper TC, Ness J, Wheeler Y, Chitnis T, Lotze T, et al. Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments. Pediatr Neurol. 2023;145:125\u201331. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.04.020.","journal-title":"Pediatr Neurol"},{"key":"778_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pediatrneurol.2024.12.015","volume":"164","author":"B Spirek","year":"2025","unstructured":"Spirek B, Brenton JN. Safety and efficacy of fingolimod and ocrelizumab in pediatric patients with multiple sclerosis. Pediatr Neurol. 2025;164:89\u201396. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.12.015.","journal-title":"Pediatr Neurol"},{"key":"778_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2023.01.011","volume":"43","author":"C Bibino\u011flu Amirov","year":"2023","unstructured":"Bibino\u011flu Amirov C, Salt\u0131k S, Yal\u00e7\u0131nkaya C, T\u00fct\u00fcnc\u00fc M, Saip S, Siva A, et al. Ocrelizumab in pediatric multiple sclerosis. Eur J Paediatr Neurol. 2023;43:1\u20135. https:\/\/doi.org\/10.1016\/j.ejpn.2023.01.011.","journal-title":"Eur J Paediatr Neurol"},{"key":"778_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105647","volume":"87","author":"Z Nasr","year":"2024","unstructured":"Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, et al. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024;87:105647. https:\/\/doi.org\/10.1016\/j.msard.2024.105647.","journal-title":"Mult Scler Relat Disord."},{"key":"778_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106539","volume":"100","author":"R Alroughani","year":"2025","unstructured":"Alroughani R, AlMojel M, Al-Hashel J, Ahmed SF. Ocrelizumab for pediatric relapsing multiple sclerosis. Mult Scler Relat Disord. 2025;100:106539. https:\/\/doi.org\/10.1016\/j.msard.2025.106539.","journal-title":"Mult Scler Relat Disord."},{"key":"778_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12879-z","volume":"272","author":"S Mar","year":"2025","unstructured":"Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, et al. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025;272:137. https:\/\/doi.org\/10.1007\/s00415-024-12879-z.","journal-title":"J Neurol"},{"key":"778_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251370529","author":"B Banwell","year":"2025","unstructured":"Banwell B, Kotulska K, Rost\u00e1sy K, Deiva K, Sato H, Filippi M, et al. Efficacy and safety of ocrelizumab compared with fingolimod in paediatric relapsing-remitting MS: results of the phase III OPERETTA 2 study. ECTRIMS 2025 late breaking oral presentations. Mult Scler J. 2025. https:\/\/doi.org\/10.1177\/13524585251370529.","journal-title":"Mult Scler J"},{"key":"778_CR39","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","volume":"269","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269:1316\u201334. https:\/\/doi.org\/10.1007\/s00415-021-10744-x.","journal-title":"J Neurol"},{"key":"778_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med"},{"key":"778_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","volume":"19","author":"HS Ng","year":"2020","unstructured":"Ng HS, Rosenbult CL, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf. 2020;19:1069\u201394. https:\/\/doi.org\/10.1080\/14740338.2020.1807002.","journal-title":"Expert Opin Drug Saf"},{"key":"778_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/13524585211044479","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28:910\u201324. https:\/\/doi.org\/10.1177\/13524585211044479.","journal-title":"Mult Scler"},{"key":"778_CR43","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024;271:1515\u201335. https:\/\/doi.org\/10.1007\/s00415-023-12007-3.","journal-title":"J Neurol"},{"key":"778_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cpt.3150","volume":"115","author":"JD Davis","year":"2024","unstructured":"Davis JD, Bravo Padros M, Conrado DJ, Ganguly S, Guan X, Hassan HE, et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin Pharmacol Ther. 2024;115:422\u201339. https:\/\/doi.org\/10.1002\/cpt.3150.","journal-title":"Clin Pharmacol Ther"},{"key":"778_CR45","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.2147\/DDDT.S315174","volume":"18","author":"Z Awada","year":"2024","unstructured":"Awada Z, Hameed N, Harel A. Profile of ofatumumab in the treatment of multiple sclerosis: design, development and place in therapy. Drug Des Devel Ther. 2024;18:5985\u201396. https:\/\/doi.org\/10.2147\/DDDT.S315174.","journal-title":"Drug Des Devel Ther"},{"key":"778_CR46","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97:e1546\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000012700.","journal-title":"Neurology"},{"key":"778_CR47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/13524585231195346","volume":"29","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Zielman R, Das Gupta A, Xi J, Stoneman D, Karlsson G, et al. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler. 2023;29:1452\u201364. https:\/\/doi.org\/10.1177\/13524585231195346.","journal-title":"Mult Scler"},{"key":"778_CR48","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B, Hartung H-P, Montalban X, Naismith RT, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19:998\u20131009. https:\/\/doi.org\/10.1016\/S1474-4422(20)30342-2.","journal-title":"Lancet Neurol"},{"key":"778_CR49","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.1173","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Bermel R, Weber MS, Hughes R, Lin C-J, Wang J, et al. Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis (1173). Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.1173.","journal-title":"Neurology"},{"key":"778_CR50","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95:e1854\u201367. https:\/\/doi.org\/10.1212\/WNL.0000000000010376.","journal-title":"Neurology"},{"key":"778_CR51","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.55563\/clinexprheumatol\/yqjz1s","volume":"41","author":"A Nassar-Sheikh Rashid","year":"2023","unstructured":"Nassar-Sheikh Rashid A, Bergkamp SC, Kampinga RE, Gouw SC, Bouts AHM, Oosterveld MJS, et al. Pharmacodynamics of rituximab in paediatric immune mediated diseases: B cell depletion and repopulation, effects on immunoglobulin levels and risk for infections. Clin Exp Rheumatol. 2023;41:2323\u201330. https:\/\/doi.org\/10.55563\/clinexprheumatol\/yqjz1s.","journal-title":"Clin Exp Rheumatol"},{"key":"778_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0365-y","volume":"17","author":"AM Khojah","year":"2019","unstructured":"Khojah AM, Miller ML, Klein-Gitelman MS, Curran ML, Hans V, Pachman LM, et al. Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol Online J. 2019;17:61. https:\/\/doi.org\/10.1186\/s12969-019-0365-y.","journal-title":"Pediatr Rheumatol Online J"},{"key":"778_CR53","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s10072-023-07281-y","volume":"45","author":"S Tarantino","year":"2024","unstructured":"Tarantino S, Proietti Checchi M, Papetti L, Monte G, Ferilli MAN, Valeriani M. Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative review. Neurol Sci. 2024;45:1913\u201330. https:\/\/doi.org\/10.1007\/s10072-023-07281-y.","journal-title":"Neurol Sci"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00778-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00778-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00778-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:54:16Z","timestamp":1790006056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00778-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":53,"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00778-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vivien X. Xie Cherng, Claire Har, Hayley Roper, Alexandra B. Kornbluh, and Ilana Kahn have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at Children\u2019s National Hospital under protocol STUDY00001421. Our institution\u2019s institutional review board determined that the research meets the criteria for a waiver of informed consent because there was no direct patient contact.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: IK, ABH. Data curation: VXC, CH, HR. Formal analysis: VXC, CH. Writing (original draft): VXC. Writing (review and editing): all authors. Supervision: IK, ABH. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}